CoChat
Sign Up
Cited by 69Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesMental Health Treatment and Access

Extended-release venlafaxine in relapse prevention for patients with major depressive disorder

Simon, Jeffrey S., Aguiar, Loren M., Kunz, Nadia R., Lei, Dean·2004·Journal of Psychiatric Research
DOI 10.1016/j.jpsychires.2003.10.004
Open this paper in CoChat — free account

Abstract

Many studies have demonstrated that venlafaxine is an efficacious and safe treatment for major depressive disorder (MDD). This double-blind, placebo-controlled study was performed to evaluate the efficacy of venlafaxine extended-release (XR) (75-225 mg/day) in the prevention of relapse of depression. Patients with MDD who responded to an 8-week course of venlafaxine XR treatment, i.e., had a score < or = 3 on the Clinical Global Impressions scale-Severity of Illness item (CGI-S) and a 21-item Hamilton Rating Scale for Depression (HAM-D(21)) score < or = 10, were randomly assigned to receive continuation treatment (up to 6 months) with venlafaxine XR (n=161) or placebo (n=157). The main efficacy outcome measure was the number of patients who experienced a relapse of depression. Relapse was defined by either a combination of a patient meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for MDD and a CGI-S score > or = 4, two consecutive CGI-S scores > or = 4, or a final CGI-S score > or = 4 for a patient who withdrew from the study. The cumulative probability of relapse was calculated using the Kaplan-Meier method of survival analysis. During the 6-month evaluation period, significantly more patients in the placebo group had a relapse of MDD than did patients who continued treatment with venlafaxine XR. Cumulative relapse rates at 3 and 6 months were 19 and 28%, respectively, for venlafaxine XR, and 44 and 52%, respectively, for placebo. This study demonstrates that venlafaxine XR is an effective and safe continuation therapy.

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2003.10.004

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The results of the first levomilnacipran ER relapse-prevention study are inconsistent with relapse-prevention outcomes reported in the literature for trials of other SNRIs versus placebo (e.g., venlafaxine, 28% vs. 52%; desvenlafaxine, 24% vs. 42%; duloxetine, 21.9% vs. 43.1%).

    “the results of the first levomilnacipran ER relapse‐prevention study are inconsistent with relapse‐prevention outcomes reported in the literature for trials of other SNRIs versus placebo (e.g., venlafaxine, 28% vs. 52%; desvenlafaxine, 24% vs. 42%; duloxetine, 21.9% vs. 43.1%; Perahia et al., 2006; Rickels et al., 2010; Simon, Aguiar, Kunz, & Lei, 2004).”

    From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Simon, Aguiar, Kunz, & Lei, 2004

Cites

Flagged first, then by citations

1 of the 53 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

Authors
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D.
Affiliations
Wyeth (US)
Corresponding author
Simon, Jeffrey S.
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2004-05
Volume
38
Issue
3
Pages
249-257
ISSN
0022-3956 (ISSN-L)
DOI
10.1016/j.jpsychires.2003.10.004
OpenAlex
W2090877369
Cited by
69
References
53
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 2 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 6 · 2013: 4 · 2012: 4
FWCI
4.60
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Psychiatric Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
Keywords
venlafaxine extended release, major depressive disorder, relapse prevention, continuation treatment, antidepressant efficacy, relapse rate, treatment response
MeSH terms
Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Placebos, Recurrence, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review